Januvia Class Action Lawsuit

Januvia (sitagliptin) is a popular oral medication prescribed to type 2 diabetics to help regulate their blood sugar levels. The drug a member of the class of drugs known as incretin mimetics, which are supposed to signal the body to release insulin after consuming food.


Januvia and the other drugs in its class have been known to carry with them serious adverse side effects, particularly pancreatitis, an inflammation of the pancreas, which can lead to pancreatic cancer. Pancreatic cancer is one of the deadliest forms of the disease, even when it is discovered in its earliest stages. 

Has Januvia Been Recalled?

Merck, the manufacturer of Januvia, has no plans at this time to recall Januvia. The company has, however, updated its packaging insert to include a warning about pancreatitis and pancreatic cancer, as ordered by the U.S. Food and Drug Administration (FDA). Moreover, the FDA has advised patients who take Januvia to be monitored regularly by their physicians for symptoms of the condition.

Januvia Class Action Lawsuits

Many patients who have been diagnosed with pancreatitis, or pancreatic cancer that they believe resulted from taking Januvia, have filed lawsuits against Merck, seeking compensation for their injuries. Plaintiffs in these lawsuits are alleging that Merck knew of the dangers of Januvia and chose not to disclose them to consumers and the medical community.

It is generally not advisable for a plaintiff who has suffered an injury from a prescription medication to join a class action lawsuit. While the complaints might be similar, the circumstances for each plaintiff can be quite different based on the severity of the injuries suffered. Class action lawsuits, if successful, require that the entire group of plaintiffs share an equal portion of a cash award. Plaintiffs that file individual, or “mass tort” lawsuits, receive compensation based on their individual circumstances.

To date, there have not been any Januvia settlements or trials, but the number of lawsuits is growing to the point where there will most likely be hundreds if not thousands brought by individuals who have been injured by this drug.

Possible Januvia Multidistrict Litigation Decision Pending

A group of Januvia plaintiffs has requested that the U.S. Judicial Panel on Multidistrict Litigation (JPML) consider forming a Januvia multidistrict litigation (MDL).  This would consolidate all Januvia lawsuits currently pending in federal courts, speeding up pretrial proceedings. A decision by the panel is due on or about July 25, 2013.

  • By submitting this form, you give RLG permission to contact you privately. Privacy policy.